Ana Presa

Ana Presa

Auto-generated profile, based on publicly available information

Ana Presa

Tâmega/Sousa Hospital Center Penafiel Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in Allergy
Verified
Journal Article
Open access
KKKanokvalai Kulthanan
Kanokvalai Kulthanan
JBJonathan Bernstein
Jonathan Bernstein
MRMichael Rudenko
Michael Rudenko
Pascale SalamehPascale Salameh
Pascale Salameh
CKChulaluk Komoltri
Chulaluk Komoltri
Torsten ZuberbierTorsten Zuberbier
Torsten Zuberbier
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.

26 June 2023 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
EGEpe Serviço de Imunoalergologia Do Centro Hospitalar Vila Nova de Gaia/Espinho
Epe Serviço de Imunoalergologia Do Centro Hospitalar Vila Nova de Gaia/Espinho
APAna Presa
Ana Presa
SGSónia Garcia
Sónia Garcia
SCSusana Cadinha
Susana Cadinha
MSMaria Sousa
Maria Sousa
Patent Blue Dye (PBD) is a synthetic blue dye commonly used in medical practice for sentinel lymph node mapping in breast cancer. The authors report the case of a patient with invasive ductal carcinoma of the left breast, who underwent unilateral mastectomy with sentinel lymph node mapping. During surgery, the patient developed violaceous urticaria and mild glottic edema. A hypersensitivity reaction to PBD was confirmed by skin prick tests and methylene blue was identified as a possible alternative dye. This article reinforces the need for greater awareness of the possible hypersensitivity reactions to PBD during surgical procedures.

22 June 2022 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
EGEpe Serviço de Imunoalergologia Do Centro Hospitalar Vila Nova de Gaia/Espinho
Epe Serviço de Imunoalergologia Do Centro Hospitalar Vila Nova de Gaia/Espinho
APAna Presa
Ana Presa
CSCátia Santa
Cátia Santa
JGJoana Gomes
Joana Gomes
JLJoana Lopes
Joana Lopes
ILInês Lopes
Inês Lopes
Introdução: A doença respiratória crónica, onde se inclui a asma, tem sido apontada como potencial fator de risco para doença COVID-19 de maior gravidade. Contudo, estudos recentes têm reportado taxas variáveis de prevalência de asma. Objetivos: Caracterizar os doentes asmáticos internados com infeção por SARS-CoV-2. Métodos: Análise retrospetiva observacional dos doentes internados com COVID-19 no Centro Hospitalar Vila Nova de Gaia/Espinho de 1 de março a 30 de junho. Resultados: Foram incluídos 237 doentes, dos quais 16 (6,8%) reportaram diagnóstico de asma. Comparativamente aos doentes não-asmáticos, os doentes com asma eram tendencialmente mais novos (70 anos vs 80 anos, p=0,027) tendo também menos comorbilidades (1 vs 2 p=0,014). Relativamente à abordagem terapêutica, os asmáticos tiveram maiores taxas de utilização de corticoterapia inalada, hidroxicloroquina e menor estabelecimento de teto terapêutico (respetivamente 50% vs 21,7%, p=0,027; 75% vs 48,9%, p=0,044; 6,3% vs 38%, p=0,011). A taxa de mortalidade foi inferior (12,5% vs 37,1%, p=0,047), comparativamente aos doentes não asmáticos. A gravidade da asma não influenciou nenhum dos outcomes analisados. Conclusão: Neste estudo, a asma não pareceu contribuir para doença COVID-19 de maior gravidade.

22 August 2023 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
CVCláudia Varandas
Cláudia Varandas
APAna Presa
Ana Presa
RFRúben Ferreira
Rúben Ferreira
SSSara Silva
Sara Silva
SSSusana L Silva
Susana L Silva
CICentro Hospitalar Do Oeste Unidade de Imunoalergologia
Centro Hospitalar Do Oeste Unidade de Imunoalergologia

26 June 2023 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
CICentro Hospitalar de Vila Nova de Gaia e Espinho Serviço de Imunoalergologia
Centro Hospitalar de Vila Nova de Gaia e Espinho Serviço de Imunoalergologia
APAna Presa
Ana Presa
CVCláudia Varandas
Cláudia Varandas
CPCentro Académico de Medicina Centro de Imunodeficiências Primárias
Centro Académico de Medicina Centro de Imunodeficiências Primárias
LCLeonor Caldeira
Leonor Caldeira
SSSusana L Silva
Susana L Silva

6 August 2025 in Gazeta Médica
Verified
Journal Article
Open access
PDF file
MGMargarida Gomes
Margarida Gomes
JSJúlia Cunha Silva
Júlia Cunha Silva
SMSara Morgado
Sara Morgado
ACAna Craveiro
Ana Craveiro
APAna Rita Presa
Ana Rita Presa
AMAna Mendes
Ana Mendes
Introduction: Severe asthma affects approximately 4%-5% of asthmatic patients and increases susceptibility to respiratory infections, including SARS-CoV-2. The impact of COVID-19 on severe asthma remains unclear. We aimed to evaluate the effects of SARS-CoV-2 infection on asthma control, quality of life, and lung function.Methods: A retrospective study of 114 severe asthma patients followed in our severe asthma unit from March 2020 to July 2022. We compared pre- and post-COVID-19 scores of the Asthma Control Test (ACT), Control of Allergic Rhinitis and Asthma Test (CARAT), Mini Asthma Quality of Life Questionnaire (mini-AQLQ) and lung function. Statistical analysis was performed using SPSS 25 (p <0.05).Results: Among 49 infected patients, ACT scores significantly decreased (p = 0.002). CARAT, mini-AQLQ, and lung function showed no significant differences.Conclusion: SARS-CoV-2 infection negatively impacted asthma control, with a significant decrease in ACT scores. Further studies are needed to clarify long-term effects.